Home / Health / Roche says FDA quick marks atezolizumab in specific form of lung cancer

Roche says FDA quick marks atezolizumab in specific form of lung cancer


ZURICH Roche Holding AG pronounced on Monday a U.S. Food and Drug Administration has postulated priority examination for atezolizumab for treating people with a specific form of lung cancer.

The nomination covers diagnosis of patients with locally modernized or metastatic non-small dungeon lung cancer (NSCLC) whose illness expresses a protein PD-L1 as dynamic by an FDA-approved test, and who have progressed on or after platinum-containing chemotherapy.

Roche had announced final month that a FDA had also postulated priority examination for atezolizumab for a diagnosis of some people with locally modernized or metastatic urothelial carcinoma.

(Reporting by Michael Shields)

Article source: http://www.reuters.com/article/us-roche-atezolizumab-idUSKCN0X80F6

InterNations.org